171 related articles for article (PubMed ID: 37619846)
41. Demystifying BRAF Mutation Status in Colorectal Liver Metastases : A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions.
Margonis GA; Boerner T; Bachet JB; Buettner S; Moretto R; Andreatos N; Sartore-Bianchi A; Wang J; Kamphues C; Gagniere J; Lonardi S; Løes IM; Wagner D; Spallanzani A; Sasaki K; Burkhart R; Pietrantonio F; Pikoulis E; Pawlik TM; Truant S; Orlandi A; Pikouli A; Pella N; Beyer K; Poultsides G; Seeliger H; Aucejo FN; Kornprat P; Kaczirek K; Lønning PE; Kreis ME; Wolfgang CL; Weiss MJ; Cremolini C; Benoist S; D'Angelica M
Ann Surg; 2023 Sep; 278(3):e540-e548. PubMed ID: 36453261
[TBL] [Abstract][Full Text] [Related]
42. Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer.
Nakaji Y; Oki E; Nakanishi R; Ando K; Sugiyama M; Nakashima Y; Yamashita N; Saeki H; Oda Y; Maehara Y
J Cancer Res Clin Oncol; 2017 Jan; 143(1):151-160. PubMed ID: 27672042
[TBL] [Abstract][Full Text] [Related]
43. Influence of microsatellite instability and KRAS and BRAF mutations on lymph node harvest in stage I-III colon cancers.
Berg M; Guriby M; Nordgård O; Nedrebø BS; Ahlquist TC; Smaaland R; Oltedal S; Søreide JA; Kørner H; Lothe RA; Søreide K
Mol Med; 2013 Sep; 19(1):286-93. PubMed ID: 23979710
[TBL] [Abstract][Full Text] [Related]
44. [Landscape of KRAS, BRAF, and PIK3CA Mutations and Clinical Features of EBV-Associated and Microsatellite Unstable Gastric Cancer].
Danishevich AM; Pospehova NI; Stroganova AM; Golovina DA; Nikulin MP; Kalinin AE; Nikolaev SE; Stilidi IS; Lyubchenko LN
Mol Biol (Mosk); 2023; 57(1):71-84. PubMed ID: 36976740
[TBL] [Abstract][Full Text] [Related]
45. Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women.
Samadder NJ; Vierkant RA; Tillmans LS; Wang AH; Weisenberger DJ; Laird PW; Lynch CF; Anderson KE; French AJ; Haile RW; Potter JD; Slager SL; Smyrk TC; Thibodeau SN; Cerhan JR; Limburg PJ
Gastroenterology; 2013 Aug; 145(2):348-56.e1-2. PubMed ID: 23665275
[TBL] [Abstract][Full Text] [Related]
46. Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer.
Ooki A; Akagi K; Yatsuoka T; Asayama M; Hara H; Takahashi A; Kakuta M; Nishimura Y; Yamaguchi K
J Surg Oncol; 2014 Dec; 110(8):982-8. PubMed ID: 25154726
[TBL] [Abstract][Full Text] [Related]
47. Molecular profiling of the colon cancer in South-Eastern Romania: Results from the MERCUR study.
Popescu RC; Tocia C; Brînzan C; Cozaru GC; Deacu M; Dumitru A; Leopa N; Mitroi AF; Nicolau A; Dumitru E
Medicine (Baltimore); 2021 Jan; 100(1):e24062. PubMed ID: 33429770
[TBL] [Abstract][Full Text] [Related]
48. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
Modest DP; Ricard I; Heinemann V; Hegewisch-Becker S; Schmiegel W; Porschen R; Stintzing S; Graeven U; Arnold D; von Weikersthal LF; Giessen-Jung C; Stahler A; Schmoll HJ; Jung A; Kirchner T; Tannapfel A; Reinacher-Schick A
Ann Oncol; 2016 Sep; 27(9):1746-53. PubMed ID: 27358379
[TBL] [Abstract][Full Text] [Related]
49. Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients.
Yoon HH; Shi Q; Alberts SR; Goldberg RM; Thibodeau SN; Sargent DJ; Sinicrope FA;
J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26160882
[TBL] [Abstract][Full Text] [Related]
50. Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report.
El Agy F; El Bardai S; El Otmani I; Benbrahim Z; Karim MH; Mazaz K; Benjelloun EB; Ousadden A; El Abkari M; Ibrahimi SA; Chbani L
PLoS One; 2021; 16(3):e0248522. PubMed ID: 33784337
[TBL] [Abstract][Full Text] [Related]
51. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
[TBL] [Abstract][Full Text] [Related]
52. Impact of microsatellite status in early-onset colonic cancer.
REACCT Collaborative
Br J Surg; 2022 Jun; 109(7):632-636. PubMed ID: 35522613
[TBL] [Abstract][Full Text] [Related]
53. Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer.
Birgisson H; Edlund K; Wallin U; Påhlman L; Kultima HG; Mayrhofer M; Micke P; Isaksson A; Botling J; Glimelius B; Sundström M
BMC Cancer; 2015 Mar; 15():125. PubMed ID: 25884297
[TBL] [Abstract][Full Text] [Related]
54. Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer.
Popovici V; Budinska E; Bosman FT; Tejpar S; Roth AD; Delorenzi M
BMC Cancer; 2013 Sep; 13():439. PubMed ID: 24073892
[TBL] [Abstract][Full Text] [Related]
55. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.
Fujiyoshi K; Yamamoto G; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
Oncol Rep; 2017 Feb; 37(2):785-792. PubMed ID: 28000889
[TBL] [Abstract][Full Text] [Related]
56. Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance).
Sinicrope FA; Mahoney MR; Yoon HH; Smyrk TC; Thibodeau SN; Goldberg RM; Nelson GD; Sargent DJ; Alberts SR;
Clin Cancer Res; 2015 Dec; 21(23):5294-304. PubMed ID: 26187617
[TBL] [Abstract][Full Text] [Related]
57. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
Velho S; Moutinho C; Cirnes L; Albuquerque C; Hamelin R; Schmitt F; Carneiro F; Oliveira C; Seruca R
BMC Cancer; 2008 Sep; 8():255. PubMed ID: 18782444
[TBL] [Abstract][Full Text] [Related]
58. Association Between Molecular Subtypes of Colorectal Tumors and Patient Survival, Based on Pooled Analysis of 7 International Studies.
Phipps AI; Alwers E; Harrison T; Banbury B; Brenner H; Campbell PT; Chang-Claude J; Buchanan D; Chan AT; Farris AB; Figueiredo JC; Gallinger S; Giles GG; Jenkins M; Milne RL; Newcomb PA; Slattery ML; Song M; Ogino S; Zaidi SH; Hoffmeister M; Peters U
Gastroenterology; 2020 Jun; 158(8):2158-2168.e4. PubMed ID: 32088204
[TBL] [Abstract][Full Text] [Related]
59. External validation of molecular subtype classifications of colorectal cancer based on microsatellite instability, CIMP, BRAF and KRAS.
Alwers E; Bläker H; Walter V; Jansen L; Kloor M; Arnold A; Sieber-Frank J; Herpel E; Tagscherer KE; Roth W; Chang-Claude J; Brenner H; Hoffmeister M
BMC Cancer; 2019 Jul; 19(1):681. PubMed ID: 31296182
[TBL] [Abstract][Full Text] [Related]
60. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
Roth AD; Delorenzi M; Tejpar S; Yan P; Klingbiel D; Fiocca R; d'Ario G; Cisar L; Labianca R; Cunningham D; Nordlinger B; Bosman F; Van Cutsem E
J Natl Cancer Inst; 2012 Nov; 104(21):1635-46. PubMed ID: 23104212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]